Clinical Research Directory

Inclusion Criteria: * Age 45-77 years at screening. * Confirmed NSCLC or solitary metastatic (oligometastatic) or pulmonary metastases from an extra thoracic primary tumor lung nodule through diagnostic biopsy * Must be eligible for curative lung resection (lobectomy). * For primary tumor, pre-ablated parenchymal tumor/lesion size ≥ 20 mm if NSCLC, or ≥ 10 mm for metastatic disease in diameter as measured from pre-operative CT image. * Willing to participate in all aspects of study protocol for duration of study. * Able to understand study requirements. * Signs informed consent form. * Boundary of tumor is at least 15 mm away from the pleura wall and/or fissure. Exclusion Criteria: * Any contraindication to bronchoscopy, for example: * Untreatable life-threatening arrhythmias. * Inability to adequately oxygenate the patient during the procedure. * Acute respiratory failure with hypercapnia (unless the patient is intubated and ventilated). * Recent myocardial infarction. * Uncorrectable coagulopathy. * Known coagulopathy. * Platelet dysfunction or platelet count \< 100 x 109 cells/L OR taking anticoagulant or antiplatelet agents that cannot be safely ceased in the opinion of the pulmonologist or surgeon. * History of major bleeding with bronchoscopy. * Suspected pulmonary hypertension. * Moderate-to-severe pulmonary fibrosis. * Severe emphysema (GOLD III/IV) or chronic obstructive pulmonary disease (COPD) within 3cm of tumor/lesion boundary: prior COPD assessment data is evaluated and PI consent is required. * Bullae \>5 centimeter (cm) located in vicinity of target tumor/lesion. * Any other severe or life-threatening comorbidity that could increase the risk of bronchoscopic MWA, for example: * American Society of Anesthesiologists (ASA) physical status classification \>P3 * Stage 3 heart failure * Severe cachexia * Severe respiratory insufficiency or hypoxia * Ongoing systemic infection. * Contraindication to general anesthesia. * Inability to stop anticoagulants (e.g., heparin, Warfarin) or antiplatelet agents (e.g. aspirin, clopidogrel) prior to procedure. * Participation in any other study in last 30 days. * Breastfeeding women or females of childbearing potential with a positive pregnancy test prior to the procedure or the intent to become pregnant during the study. * Life expectancy of less than 6 months. * Prior radiation therapy treatment in the target lobe. * Implantable pacemaker or defibrillator.